November 11, 2021
Liquid biopsy is a powerful tool for matching cancer patients with targeted therapies and for cancer recurrence monitoring.
November 4, 2021
The use of genomic profiling and testing in cancer is helping clinicians and patients better understand the key drivers of a patient’s tumour and inform more precise treatment decisions.
November 1, 2021
Lab Genomics Announces MolDX® Coverage for Follow It® Circulating Tumor DNA Assay in Partnership with Canexia Health
FOUNTAIN VALLEY, Calif.
October 14, 2021
The FDA is now approving biomarker-informed therapies on a routine basis, yet there is significant disparity in patient access to molecular profiling that would match cancer patients to these targeted treatments.